Silexion Therapeutics Receives Approval From Germany's Federal Institute For Drugs And Medical Devices To Start Its Planned Phase 2/3 Clinical Study Of SIL204 In Participants With Locally Advanced Pancreatic Cancer

뉴스 본문을 불러오고 있어요.

Silexion Therapeutics Receives Approval From Germany's Federal Institute For Drugs And Medical Devices To Start Its Planned Phase 2/3 Clinical Study Of SIL204 In Participants With Locally Advanced Pancreatic Cancer | 웨이프 WAPE

Silexion Therapeutics Receives Approval From Germany's Federal Institute For Drugs And Medical Devices To Start Its Planned Phase 2/3 Clinical Study Of SIL204 In Participants With Locally Advanced Pancreatic Cancer

기사 요약

관련 종목

댓글 —